← Back to feed

CelLBxHealth plc

CLBX · AIM · Health Care · mcap £9.3m today

All announcements

All RNS · 34 Key events · 31

11 Aug 26

Parsortix CTCs used for Brain Cancer detection

· Independent peer-reviewed study supports Parsortix® use in GBM
RNS 9714385 ↗
03 Aug 26

Parsortix CTCs used for ADC target assessment

· Parsortix® used to detect ADC-relevant targets on CTCs from breast and ovarian cancer patients
RNS 9699754 ↗
16 Jul 26

Issue of Share Options

Guildford, UK and Plymouth Meeting, U.S. - 16 July 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces...
RNS 9671300 ↗
15 Jul 26

Q2 and First Half Year Results ended 30 June 2026

Q2 and First Half Year Results ended 30 June 2026
RNS 9668944 ↗
14 Jul 26

AGM Statement

Guildford, UK and Plymouth Meeting, U.S. - 14 July 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, will hold its...
RNS 9666597 ↗
06 Jul 26

Directorate Change

Guildford, UK and Plymouth Meeting, U.S. - 6 July 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that...
RNS 9654665 ↗
22 Jun 26

Final Results

Preliminary Results for the year ended 31 December 2025
RNS 9628683 ↗
29 May 26

MSA with Global Pharmaceutical Company

Guildford, UK and Plymouth Meeting, U.S. - 29 May 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that...
RNS 9590876 ↗
18 May 26

Collaboration with AdventHealth for two studies

Collaboration with AdventHealth for two studies monitoring CTCs to improve cancer care
RNS 9571893 ↗
11 May 26

Q1 trading update and outlook for 2026

Guildford, UK and Plymouth Meeting, U.S. - 11 May 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumor cell (CTC) solutions for use in research, drug development and clinical oncology, provides a...
RNS 9560482 ↗
30 Apr 26

Confirmation of Q1 trading update

Guildford, UK and Plymouth Meeting, U.S. - 30 April 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumor cell (CTC) solutions for use in research, drug development and clinical oncology, announces...
RNS 9545361 ↗
20 Apr 26

Research Collaboration with The Royal Marsden

Research Collaboration with The Royal Marsden NHS Foundation Trust
RNS 9527007 ↗
16 Apr 26

Board changes - Replacement New CEO

The following amendment has been made to the 'Board changes' announcement released on 12 January 2026 at 7:00 a.m. under RNS No 4265O.
RNS 9524689 ↗
13 Feb 26

Aligning Regulatory Approach with Commercial Needs

CelLBxHealth strengthens cost discipline by aligning FDA regulatory approach with current commercial needs
RNS 9429145 ↗
16 Jan 26

Preliminary Fourth Quarter 2025 Financial Results

Guildford, UK and Plymouth Meeting, US - 16 January 2026 - CelLBxHealth plc (AIM:CLBX), a leader in circulating tumour cell (CTC) intelligence, with tests and services supporting research, drug development and clinical oncology, announces an update on 2025...
RNS 9357562 ↗
12 Jan 26

Directorate Change New CEO

Guildford, UK and Plymouth Meeting, US - CelLBxHealth plc (AIM: CLBX), a leader in circulating tumour cell (CTC) intelligence, with tests and services supporting research, drug development and clinical oncology, is pleased to announce that further to the...
RNS 9346339 ↗
23 Dec 25

Holding(s) in Company Holder at 25–30 %

TR-1: Standard form for notification of major holdings
RNS 9315322 ↗
19 Dec 25

PDMR Dealing and ESOT Share Purchase Director buys

Guildford, UK - 19 December 2025 - CELLBXHEALTH plc (AIM:CLBX), a leader in circulating tumour cell (CTC) intelligence, with tests and services supporting research, drug development and clinical oncology, announces that, following the Oversubscribed...
RNS 9309949 ↗
15 Dec 25

Results of General Meeting and Board Changes New CEO

Results of General Meeting and Proposed Board Changes
RNS 9297820 ↗
02 Dec 25

Additional Subscription

CELLBXHEALTH plc (AIM: CLBX), a leader in circulating tumour cell (CTC) intelligence is pleased to announce that further to the closing of the Retail Offer yesterday, Conifer Management, LLC, on behalf of the Acacia funds ("Acacia''), has subscribed for a...
RNS 9270446 ↗
01 Dec 25

Result of Retail Offer

The Board of CELLBXHEALTH plc (the "Company") (AIM: CLBX), a leader in circulating tumour cell (CTC) intelligence, is pleased to announce that the Retail Offer launched on 25 November 2025 has now closed, raising gross proceeds of approximately £0.96 million.
RNS 9268537 ↗
25 Nov 25

Update to Admission of Fundraising Shares

CELLBXHEALTH plc (AIM: CLBX), a leader in circulating tumour cell (CTC) intelligence announces, following the conclusion of the oversubscribed Placing, the following update with regards Admission of the Fundraising Shares.
RNS 9256767 ↗
25 Nov 25

Launch of Retail Offer

The Board of CelLBxHealth plc (the "Company") is pleased to announce a retail offer via BookBuild (the "Retail Offer") of new ordinary shares ("Ordinary Shares") in the capital of the Company (the "Retail Offer Shares") at an issue price of 1.0 pence per...
RNS 9255419 ↗
25 Nov 25

Result of Oversubscribed Placing and Subscription

596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED ("MAR").
RNS 9255411 ↗
24 Nov 25

Proposed Placing and Subscription

UNLESS OTHERWISE INDICATED, CAPITALISED TERMS IN THIS ANNOUNCEMENT HAVE THE MEANINGS GIVEN TO THEM IN THE DEFINITIONS SECTION INCLUDED IN APPENDIX I.
RNS 9254164 ↗
18 Nov 25

QIAGEN Collaboration and Co-Marketing Agreement

Collaboration and co-marketing agreement with QIAGEN to advance CTC-based research with its pharmaceutical partners
RNS 9239868 ↗
05 Nov 25

Further Update on Funding

CELLBXHEALTH plc (AIM:CLBX), a global leader in circulating tumour cell (CTC) intelligence, announces, further to the interim results of 9 October 2025, the Company currently has a cash runway into early 2026.
RNS 9215074 ↗
05 Nov 25

CelLBxHealth Presents Proof-of-Concept Study

CelLBxHealth presents proof-of-concept study using Roche Tissue Diagnostics' workflow at world-leading drug development conference
RNS 9212862 ↗
04 Nov 25

Expert Consensus on CTCs; Update on Funding

Independent Expert Consensus Confirms Clinical Relevance of CTCs and Identifies Parsortix Platform as Leading Next-Generation Technology
RNS 9210164 ↗
16 Oct 25

Appointments: Interim CEO and senior board advisor New CEO

APPOINTMENT OF INTERIM CEO AND SENIOR BOARD ADVISOR
RNS 9174005 ↗
08 Oct 25

Strategy Update

Appointment of Executive Chairman, proposed change of name and strategy update
RNS 9156893 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.